Virtual Library

Start Your Search

  • ELCC 2017

    The 7th European Lung Cancer Conference

    Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland

    Presentation Date(s):  
    • May 5 – 8, 2017
    • Total Presentations: 359

Filter Results:

Show Only Available Presentations

  • +

    Management of brain metastases

    • Type: Educational session
    • Presentations: 5
    • Moderators:S. Ekman
    • Coordinates: 5/05/2017, 14:30 - 16:00, Room B
    • +

      Molecular characteristics of brain metastases: Are they different?

      14:30 - 14:50  |  Author(s): S. Ekman

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Systemic treatment of brain metastases

      14:50 - 15:10  |  Author(s): J.C. Yang

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Local management of brain metastases: The surgeon’s perspective

      15:10 - 15:30  |  Author(s): M. De Praeter

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Radiation therapy of brain metastases

      15:30 - 15:50  |  Author(s): J.D. Zindler

      • Abstract

      No abstract available for this presentation

    • +

      Questions and Answers

      15:50 - 16:00

      • Abstract

      No abstract available for this presentation

  • +

    Targeted therapies and management of brain metastasis

    • Type: Proffered Paper session
    • Presentations: 7
    • Moderators:D.P. Carbone
    • Coordinates: 5/06/2017, 16:45 - 18:15, Room A
    • +

      1O - ROS1 immunocytochemistry on cytological specimens in patients with non-small cell lung cancer

      16:45 - 16:57  |  Author(s): T. Vlajnic

      • Abstract

      Loading...

    • +

      86O - Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: The story so far

      16:57 - 17:09  |  Author(s): E. Smit

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Invited Discussant 1O and 86O

      17:09 - 17:24  |  Author(s): D.P. Carbone

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      3O - Innate resistance in EGFR mutant non-small cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs)

      17:24 - 17:36  |  Author(s): R. Rosell

      • Abstract

      Loading...

    • +

      87O - Brigatinib in ALK+ NSCLC pts with intracranial CNS metastases in 2 clinical trials

      17:36 - 17:48  |  Author(s): M. Tiseo

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      88O - CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts)

      17:48 - 18:00  |  Author(s): K.L. Reckamp

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Invited Discussant 3O, 87O and 88O

      18:00 - 18:15  |  Author(s): S. Popat

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Targeted therapies and immunotherapies

    • Type: Poster Discussion session
    • Presentations: 10
    • Moderators:S. Ekman
    • Coordinates: 5/07/2017, 14:45 - 15:45, Room W
    • +

      89PD - Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC

      14:45 - 14:45  |  Author(s): D. Cortinovis

      • Abstract

      Loading...

    • +

      90PD - Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

      14:45 - 14:45  |  Author(s): R.S. Herbst

      • Abstract

      Loading...

    • +

      91PD_PR - Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

      14:45 - 14:45  |  Author(s): S.I. Rothschild

      • Abstract

      Loading...

    • +

      Invited Discussant 89PD, 90PD and 91PD_PR

      14:45 - 15:00  |  Author(s): S. Ekman

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Discussion

      15:00 - 15:15

      • Abstract

      No abstract available for this presentation

    • +

      92PD - First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials

      15:15 - 15:15  |  Author(s): M. Schuler

      • Abstract

      Loading...

    • +

      93PD - Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)

      15:15 - 15:15  |  Author(s): J. Corral

      • Abstract

      Loading...

    • +

      94PD - Adverse events self-reported by patients with advanced non-small cell lung cancer treated with osimertinib or chemotherapy

      15:15 - 15:15  |  Author(s): M. Sebastian

      • Abstract

      Loading...

    • +

      Invited Discussant 92PD, 93PD and 94PD

      15:15 - 15:30  |  Author(s): N. Reguart

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Discussion

      15:30 - 15:45

      • Abstract

      No abstract available for this presentation